Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome

To assess the angiotensin II blocker effects on platelet (PL) aggregation in patients with arterial hypertension (AH) and metabolic syndrome (MS). In total, 35 patients received losartan for 16 weeks. Dynamics of plasma and PL lipid peroxidation, blood and PL antioxidant protection, and PL aggregati...

Full description

Saved in:
Bibliographic Details
Main Authors: I. N. Medvedev, T. A. Kumova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2008-10-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1627
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849688691089342464
author I. N. Medvedev
T. A. Kumova
author_facet I. N. Medvedev
T. A. Kumova
author_sort I. N. Medvedev
collection DOAJ
description To assess the angiotensin II blocker effects on platelet (PL) aggregation in patients with arterial hypertension (AH) and metabolic syndrome (MS). In total, 35 patients received losartan for 16 weeks. Dynamics of plasma and PL lipid peroxidation, blood and PL antioxidant protection, and PL aggregation activity was investigated and analyzed using Student t-test. Losartan therapy improved peroxidation and PL aggregation parameters in patients with AH and MS.
format Article
id doaj-art-e6e77a0b723645e08f7aa94fe6b7e560
institution DOAJ
issn 1560-4071
2618-7620
language Russian
publishDate 2008-10-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-e6e77a0b723645e08f7aa94fe6b7e5602025-08-20T03:21:54Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202008-10-010553551412Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndromeI. N. Medvedev0T. A. Kumova1Курский институт социального образования – филиал Российского государственного социального университетаКурский институт социального образования – филиал Российского государственного социального университетаTo assess the angiotensin II blocker effects on platelet (PL) aggregation in patients with arterial hypertension (AH) and metabolic syndrome (MS). In total, 35 patients received losartan for 16 weeks. Dynamics of plasma and PL lipid peroxidation, blood and PL antioxidant protection, and PL aggregation activity was investigated and analyzed using Student t-test. Losartan therapy improved peroxidation and PL aggregation parameters in patients with AH and MS.https://russjcardiol.elpub.ru/jour/article/view/1627arterial hypertensionmetabolic syndromeplateletslosartan
spellingShingle I. N. Medvedev
T. A. Kumova
Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
Российский кардиологический журнал
arterial hypertension
metabolic syndrome
platelets
losartan
title Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
title_full Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
title_fullStr Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
title_full_unstemmed Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
title_short Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
title_sort reduced platelet aggregation in losartan treated patients with arterial hypertension and metabolic syndrome
topic arterial hypertension
metabolic syndrome
platelets
losartan
url https://russjcardiol.elpub.ru/jour/article/view/1627
work_keys_str_mv AT inmedvedev reducedplateletaggregationinlosartantreatedpatientswitharterialhypertensionandmetabolicsyndrome
AT takumova reducedplateletaggregationinlosartantreatedpatientswitharterialhypertensionandmetabolicsyndrome